Trial Profile
A open-label, non-randomized, phase II, pilot study to evaluate the efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel; Vinorelbine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 27 Nov 2015 New trial record